Efficacy and Safety of GENOSS® SES in Patients With Acute Coronary Syndrome (GENOSS ACS)

\<Inclusion Criteria\> 1. Patients of 19 and over 2. Patients with acute coronary syndrome treated with GENOSS SES 3. Participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written informed consent as study participants. \<Exclusion Criteria\> 1. Patients who are contraindicated in the use of heparin, aspirin, clopidogrel, sirolimus, cobalt chromium and contrast agents \- However, patients with hypersensitivity to contrast agents may be eligible if it can be controlled by steroids and pheniramine. Patients with known anaphylaxis are excluded 2. Patients who are pregnant or planning to become pregnant 3. Patients scheduled to undergo surgery requiring the discontinuation of antiplatelet agents within 12 months from registration. 4. Patients with a life expectancy of less than 1 year 5. Patients who presented with cardiogenic shock at admission and are predicted to have a low chance of survival based on medical judgment. 6. Patients who have already received treatment with another DES (Drug Eluting Stent), BVS (Bioresorbable Vascular Scaffolds), or BMS (Bare Metal Stent) at the time of registration. 7. Patients currently participating in a randomized controlled trial involving medical devices.